Literature DB >> 7773699

Increased NMDA-induced excitability during ethanol withdrawal: a behavioural and histological study.

M Davidson1, B Shanley, P Wilce.   

Abstract

Intrahippocampal injections of N-methyl-D-aspartic acid (NMDA) leads to neurodegeneration in a dose-dependent manner. Chronic administration of ethanol to animals leads to CNS tolerance and dependence. Hyperexcitability following ethanol withdrawal is thought to be related to increased sensitivity of the NMDA receptors. The purpose of this study was to investigate this predisposition to hyperexcitability by intrahippocampal injection of low dose of NMDA. Using control and ethanol-withdrawn male Wistar rats, behavioural indices were determined immediately after injection and morphological damage was assessed after a period of recovery. There was significantly increased hyperactivity in the ethanol-treated rats immediately after injection. Morphological damage resulting from 5 nmol of NMDA was significantly greater in the CA3 region of the hippocampus in these animals. These data support the hypothesis that ethanol dependence and subsequent withdrawal is associated with increased sensitivity to NMDA which may underlie ethanol withdrawal-associated brain damage.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7773699     DOI: 10.1016/0006-8993(94)01440-s

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  24 in total

Review 1.  Antireward, compulsivity, and addiction: seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction.

Authors:  George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2017-01-03       Impact factor: 4.530

2.  Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia.

Authors:  Jana Ruda-Kucerova; Zuzana Babinska; Tibor Stark; Vincenzo Micale
Journal:  Neurotox Res       Date:  2017-04-18       Impact factor: 3.911

3.  The effects of a single memantine treatment on behavioral alterations associated with binge alcohol exposure in neonatal rats.

Authors:  Nirelia M Idrus; Nancy N H McGough; Michael J Spinetta; Jennifer D Thomas; Edward P Riley
Journal:  Neurotoxicol Teratol       Date:  2011-05-03       Impact factor: 3.763

4.  MK-801 administration during neonatal ethanol withdrawal attenuates interpositus cell loss and juvenile eyeblink conditioning deficits.

Authors:  Brandt W Young; Dale R Sengelaub; Joseph E Steinmetz
Journal:  Alcohol       Date:  2010-07-03       Impact factor: 2.405

Review 5.  Neurobiology of addiction: a neurocircuitry analysis.

Authors:  George F Koob; Nora D Volkow
Journal:  Lancet Psychiatry       Date:  2016-08       Impact factor: 27.083

6.  Ethanol impairs microtubule formation via interactions at a microtubule associated protein-sensitive site.

Authors:  Katherine J Smith; Tracy R Butler; Mark A Prendergast
Journal:  Alcohol       Date:  2013-09-18       Impact factor: 2.405

7.  Behavioral deficits and cellular damage following developmental ethanol exposure in rats are attenuated by CP-101,606, an NMDAR antagonist with unique NR2B specificity.

Authors:  B Lewis; K A Wellmann; A M H Kehrberg; M L Carter; T Baldwin; M Cohen; S Barron
Journal:  Pharmacol Biochem Behav       Date:  2011-10-20       Impact factor: 3.533

Review 8.  Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence.

Authors:  Barbara J Mason; Charles J Heyser
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-03       Impact factor: 4.388

9.  Potentiation of N-methyl-D-aspartate receptor-mediated neuronal injury during methamphetamine withdrawal in vitro requires co-activation of IP3 receptors.

Authors:  Katherine J Smith; Tracy R Butler; Rachel L Self; Brittany B Braden; Mark A Prendergast
Journal:  Brain Res       Date:  2007-10-18       Impact factor: 3.252

Review 10.  Addictions Neuroclinical Assessment: A reverse translational approach.

Authors:  Laura E Kwako; Reza Momenan; Erica N Grodin; Raye Z Litten; George F Koob; David Goldman
Journal:  Neuropharmacology       Date:  2017-03-07       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.